AstraZeneca (LON:AZN) Raised to “Hold” at Deutsche Bank Aktiengesellschaft

Deutsche Bank Aktiengesellschaft upgraded shares of AstraZeneca (LON:AZN) to a hold rating in a research note issued to investors on Monday morning, Marketbeat.com reports.

AZN has been the topic of several other reports. JPMorgan Chase & Co. reissued an overweight rating on shares of AstraZeneca in a research report on Thursday, April 4th. Barclays reissued an overweight rating and set a £125 ($155.61) price target on shares of AstraZeneca in a research report on Monday, April 8th. Shore Capital reissued a buy rating on shares of AstraZeneca in a research report on Monday. UBS Group cut their price target on shares of AstraZeneca from £107 ($133.20) to GBX 9,900 ($123.24) and set a sell rating on the stock in a research report on Monday, February 12th. Finally, BMO Capital Markets reissued an outperform rating on shares of AstraZeneca in a research report on Monday, February 12th. One equities research analyst has rated the stock with a sell rating, two have assigned a hold rating and six have given a buy rating to the stock. According to MarketBeat, the stock presently has an average rating of Moderate Buy and an average price target of £115.43 ($143.69).

AstraZeneca Price Performance

Shares of LON AZN opened at £108.62 ($135.22) on Monday. The firm has a market cap of £168.36 billion, a PE ratio of 3,584.82, a PEG ratio of 0.89 and a beta of 0.19. The company has a current ratio of 0.82, a quick ratio of 0.59 and a debt-to-equity ratio of 75.70. AstraZeneca has a 1-year low of GBX 9,461 ($117.78) and a 1-year high of £123.92 ($154.26). The company has a fifty day moving average price of £103.49 and a 200 day moving average price of £104.25.

AstraZeneca Increases Dividend

The company also recently announced a dividend, which was paid on Monday, March 25th. Stockholders of record on Thursday, February 22nd were issued a GBX 156 ($1.94) dividend. This represents a dividend yield of 1.49%. This is a boost from AstraZeneca’s previous dividend of $71.80. The ex-dividend date was Thursday, February 22nd. AstraZeneca’s dividend payout ratio is presently 7,524.75%.

About AstraZeneca

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company's marketed products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Lokelma, Roxadustat, Andexxa, Crestor, Seloken, Onglyza, Bydureon, Fasenra, Breztri, Symbicort, Saphnelo, Tezspire, Pulmicort, Bevespi, and Daliresp for cardiovascular, renal, metabolism, and oncology.